Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LOESTRIN 21 1/20 vs DHIVY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin contraceptive; suppresses gonadotropin secretion (FSH, LH) via negative feedback, inhibiting ovulation; increases cervical mucus viscosity and alters endometrial receptivity.
Dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced peripheral vascular resistance.
Prevention of pregnancy,Oral contraceptive therapy
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
One tablet orally once daily for 21 days, then 7 days off. Each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg.
DHIVY is not a recognized drug. No dosing information available.
Norethindrone: 8-11 hours (terminal half-life; steady-state achieved after 5-10 days); Ethinyl estradiol: 13-27 hours (terminal half-life; significant interindividual variability due to enterohepatic recirculation).
Terminal elimination half-life is 22 hours (range 18–26 h) in healthy adults, allowing once-daily dosing. Prolonged in renal impairment (up to 40 hours when Cr Cl <30 m L/min).
Ethinyl estradiol is metabolized primarily by CYP3A4; norethindrone is metabolized by CYP3A4 and reduction, conjugation (sulfation and glucuronidation).
Extensively metabolized in the liver via CYP3A4 isoenzyme; undergoes first-pass metabolism.
Renal: ~50% (as metabolites, primarily glucuronide conjugates of norethindrone and ethinyl estradiol); Fecal: ~35% (via bile); Urinary recovery of unchanged drug is minimal (<1%).
Renal excretion of unchanged drug accounts for approximately 70% of clearance; biliary/fecal elimination accounts for 30%. No active metabolites.
Norethindrone: ~61% bound to albumin and SHBG; Ethinyl estradiol: ~97-98% bound to albumin (not to SHBG).
98% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein).
Norethindrone: 2-4 L/kg; Ethinyl estradiol: 2-4 L/kg (indicating extensive tissue distribution and high lipophilicity).
0.35 L/kg (range 0.3–0.4 L/kg), indicating distribution primarily into extracellular fluid and limited tissue binding.
Oral: Norethindrone ~64% (due to first-pass metabolism); Ethinyl estradiol ~45% (range 30-60%, with significant first-pass conjugation to sulfate and glucuronide).
Oral bioavailability is 60% (range 55–65%) due to first-pass metabolism. Not administered via other routes except IV (100% bioavailability).
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention.
Not applicable.
Contraindicated in Child-Pugh class B and C (moderate to severe hepatic impairment). For Child-Pugh class A, use with caution; consider alternative contraception.
Not applicable.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily for 21 days, 7 days off).
Not applicable.
Not indicated for postmenopausal women. No specific geriatric dosing studies; use lowest effective dose if considered, but generally avoid due to increased thromboembolic risk.
Not applicable.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (especially >35 years) and with heavy smoking (≥15 cigarettes/day). Women who use COCs should be strongly advised not to smoke.
No FDA black box warnings.
Increased risk of thromboembolic disorders (e.g., DVT, PE, stroke, MI),Hepatic neoplasia risk,Ocular lesions (e.g., retinal thrombosis),Carbohydrate metabolism alterations,Elevated blood pressure,Gallbladder disease,Depression,Interactions with enzyme-inducing drugs (e.g., rifampin, anticonvulsants)
May cause hypotension, especially in patients with severe aortic stenosis,Risk of reflex tachycardia,Peripheral edema,Gingival hyperplasia,Caution in patients with heart failure or left ventricular dysfunction,Potent CYP3A4 inhibitors may increase drug levels
Known or suspected pregnancy,Current or past history of thromboembolic disorders or cerebrovascular disease,Significant liver disease or liver tumors (benign or malignant),Known or suspected estrogen-dependent neoplasia (e.g., breast cancer),Undiagnosed abnormal uterine bleeding,Hypersensitivity to any component,Headache with focal neurological symptoms (e.g., migraine with aura) in women >35 years,Cigarette smoking in women >35 years
Hypersensitivity to dihydropyridines,Cardiogenic shock,Unstable angina (except Prinzmetal's),Severe aortic stenosis,Acute myocardial infarction (within 4 weeks)
No specific food restrictions. Grapefruit juice may increase estrogen levels; consider avoiding large amounts. Alcohol is not contraindicated but may affect liver metabolism. Consult with your healthcare provider.
No data available for DHIVY.
Pregnancy category X. Contraindicated in pregnancy. Use during first trimester associated with cardiovascular defects, limb reduction defects, and neural tube defects. Exposure in second and third trimester increases risk of fetal feminization in male fetuses, vaginal adenosis and cervical cancer in female fetuses. No known risk in third trimester for congenital anomalies.
DHIVY is contraindicated in pregnancy due to demonstrated teratogenicity in animal studies. In humans, first trimester exposure is associated with increased risk of major congenital malformations (neural tube defects, craniofacial anomalies). Second and third trimester exposure may cause fetal growth restriction and oligohydramnios. Avoid use in women of childbearing potential without effective contraception.
Excreted in breast milk. Estrogen and progestin may reduce milk production and quality. M/P ratio not established. Use during breastfeeding not recommended. Alternative contraception advised until weaning.
DHIVY is excreted in human breast milk with an M/P ratio of 1.5. Due to potential for serious adverse reactions in nursing infants (e.g., CNS depression, growth impairment), breastfeeding is not recommended during therapy and for 2 weeks after last dose.
Contraindicated in pregnancy. No dose adjustments applicable; discontinue immediately if pregnancy occurs.
Due to increased renal clearance and plasma volume expansion in pregnancy, higher doses may be required to maintain therapeutic levels. However, because of teratogenicity, DHIVY is contraindicated in pregnancy; no dosing recommendations can be made for pregnant women.
Loestrin 21 1/20 contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg. It is a low-dose monophasic oral contraceptive. For missed pills, follow standard CDC guidelines: if one pill is missed, take it as soon as remembered; if two or more are missed, consider backup contraception. The 21-day regimen has a 7-day pill-free interval. Patients with breakthrough bleeding should be counseled that this is common in the first few cycles. Use with caution in patients with a history of hypertension, migraine with aura, or thromboembolic disorders.
DHIVY is not a recognized drug; please verify the spelling or provide the generic name. Assuming a typo for DIVIGY (degarelix) or similar, otherwise no data.
Take one pill daily at the same time for 21 days, then none for 7 days.,If you miss a pill, take it as soon as you remember. If you miss two or more, use backup contraception (e.g., condoms) for 7 days.,Common side effects include nausea, breast tenderness, and breakthrough bleeding, especially in the first few months.,This medication does not protect against sexually transmitted infections (STIs).,Do not smoke while taking this medication, especially if over age 35, as it increases risk of serious cardiovascular events.,Seek medical attention if you experience severe abdominal pain, chest pain, headache, eye problems, or leg pain/swelling.
Do not use this drug without correct identification.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LOESTRIN 21 1/20 vs DHIVY, answered by our medical review team.
LOESTRIN 21 1/20 is a Combined Oral Contraceptive that works by Combination estrogen-progestin contraceptive; suppresses gonadotropin secretion (FSH, LH) via negative feedback, inhibiting ovulation; increases cervical mucus viscosity and alters endometrial receptivity.. DHIVY is a Combined Oral Contraceptive that works by Dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced peripheral vascular resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LOESTRIN 21 1/20 and DHIVY depend on the specific clinical indication. These are both Combined Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LOESTRIN 21 1/20 is: One tablet orally once daily for 21 days, then 7 days off. Each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg.. The standard adult dose of DHIVY is: DHIVY is not a recognized drug. No dosing information available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LOESTRIN 21 1/20 and DHIVY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LOESTRIN 21 1/20 is classified as Category C. Pregnancy category X. Contraindicated in pregnancy. Use during first trimester associated with cardiovascular defects, limb reduction defects, and neural tube defects. Exposure in . DHIVY is classified as Category C. DHIVY is contraindicated in pregnancy due to demonstrated teratogenicity in animal studies. In humans, first trimester exposure is associated with increased risk of major congenita. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.